(Q36974707)

17 August 2017

1 reference

title

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents (English)

1 reference

17 August 2017

Mark Bishton

1

0 references

Ricky W Johnstone

object named as

Ricky Johnstone

3

0 references

author name string

Melita Kenealy

2

1 reference

17 August 2017

Walid Rasheed

4

1 reference

17 August 2017

H Miles Prince

5

1 reference

17 August 2017

language of work or name

1 reference

1 October 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1439-1449

1 reference

Worms gang up on bacteria

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Chromatin modification, leukaemia and implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Polycomb silencers control cell fate, development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

The fundamental role of epigenetics in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

17-AAG: mechanisms of antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Future directions for the use of hypomethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1439

Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1124/MOL.105.016154

Identifiers

DOI

10.1586/14737140.7.10.1439

1 reference

17 August 2017

1 reference